These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38063316)

  • 21. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
    Yi Z; Ma F; Rong G; Guan Y; Li C; Xu B
    Cancer Commun (Lond); 2020 Jun; 40(6):260-269. PubMed ID: 32436611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
    Saleh MM; Scheffler M; Merkelbach-Bruse S; Scheel AH; Ulmer B; Wolf J; Buettner R
    J Thorac Oncol; 2022 Jan; 17(1):76-88. PubMed ID: 34601169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
    Sande CM; Chang B; Monga V; Bossler AD; Ma D
    Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
    Iacopetta B; Russo A; Bazan V; Dardanoni G; Gebbia N; Soussi T; Kerr D; Elsaleh H; Soong R; Kandioler D; Janschek E; Kappel S; Lung M; Leung CS; Ko JM; Yuen S; Ho J; Leung SY; Crapez E; Duffour J; Ychou M; Leahy DT; O'Donoghue DP; Agnese V; Cascio S; Di Fede G; Chieco-Bianchi L; Bertorelle R; Belluco C; Giaretti W; Castagnola P; Ricevuto E; Ficorella C; Bosari S; Arizzi CD; Miyaki M; Onda M; Kampman E; Diergaarde B; Royds J; Lothe RA; Diep CB; Meling GI; Ostrowski J; Trzeciak L; Guzinska-Ustymowicz K; Zalewski B; Capellá GM; Moreno V; Peinado MA; Lönnroth C; Lundholm K; Sun XF; Jansson A; Bouzourene H; Hsieh LL; Tang R; Smith DR; Allen-Mersh TG; Khan ZA; Shorthouse AJ; Silverman ML; Kato S; Ishioka C;
    Ann Oncol; 2006 May; 17(5):842-7. PubMed ID: 16524972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
    Du L; Kim JJ; Shen J; Chen B; Dai N
    Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.
    Javier BM; Yaeger R; Wang L; Sanchez-Vega F; Zehir A; Middha S; Sadowska J; Vakiani E; Shia J; Klimstra D; Ladanyi M; Iacobuzio-Donahue CA; Hechtman JF
    Oncotarget; 2016 Aug; 7(32):50875-50882. PubMed ID: 27248473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
    Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
    Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted deep sequencing reveals
    Chen X; Hu M; Chen Y; Li A; Hua Y; Jiang H; Li H; Lin M
    Scand J Gastroenterol; 2022 Apr; 57(4):465-472. PubMed ID: 34978498
    [No Abstract]   [Full Text] [Related]  

  • 33. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
    Li W; Qiu T; Guo L; Ying J; Zhou A
    Pathol Res Pract; 2019 Mar; 215(3):483-489. PubMed ID: 30611619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
    Hayama T; Hashiguchi Y; Okamoto K; Okada Y; Ono K; Shimada R; Ozawa T; Toyoda T; Tsuchiya T; Iinuma H; Nozawa K; Matsuda K
    Int J Colorectal Dis; 2019 Aug; 34(8):1491-1496. PubMed ID: 31309326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-small-cell lung cancer patients harboring
    Zhang C; Wang K; Lin J; Wang H
    Future Oncol; 2022 Sep; 18(27):3031-3041. PubMed ID: 36065989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.